EQL Pharma AB (publ) (STO:EQL)

Market Cap	1.69B
Revenue (ttm)	399.07M
Net Income (ttm)	29.61M
Shares Out	29.53M
EPS (ttm)	0.98
PE Ratio	58.66
Forward PE	35.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,065
Average Volume	23,502
Open	54.40
Previous Close	56.00
Day's Range	54.40 - 58.00
52-Week Range	46.55 - 98.60
Beta	0.41
RSI	53.68
Earnings Date	Feb 3, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.